Features

Novo Nordisk’s bid to best a previous offer from Pfizer to acquire the bio/pharma company, Metsera, is the latest in the competitive obesity drug market. What are the assets the companies are vying for, and how do they stack up against other contenders in the obesity drug market?

Partnering deals and MA& among the large bio/pharma companies and smaller companies not only reflect strategic decisions by the bio/pharma majors to build their product portfolios, but also put these smaller companies on the industry map. Which companies are making the mark in 2025?

Roche released its earnings for the first nine months of 2025, which saw its pharmaceutical revenues increase by 9% at constant exchange rates. Its top five growth drivers – Phesgo, Xolair, Hemlibra, Vabysmo and Ocrevus – achieved total sales of nearly $20 billion. Will momentum continue?

mRNA technology was lifted into commercial success during the pandemic, with two major mRNA vaccines, Pfizer’s/BioNTech’s Comirnaty and Moderna’s Spikevax. With that market closing, where does the mRNA pipeline stand? Is oncology the next wave?

The biotech industry stands at a crossroads. The interplay between innovation, policy changes, and pricing challenges will shape the future of biotech, influencing how companies navigate funding, research, and product development.

How are small-molecule drugs faring in new drug approvals by FDA thus far in 2025? Where does the industry stand now and comparative to recent trends? DCAT Value Chain Insights looks at the products and companies.

FDA has introduced a new pilot program to prioritize abbreviated new drug applications for generic drugs that use US-based manufacturing and testing, the latest in a series of moves by the Administration to incentivize US-based manufacturing.

Antibody drug conjugates (ADCs) are a growing modality in the oncology drug market. Bispecific ADCs are an emerging subset of ADCs with several investigational drug candidates advancing. The latest developments in the ADC drug market.

For the bio/pharma industry, it has been again another active week on the US policy front, with additional moves relating to tariffs, the federal government shutdown, and drug pricing. What is the latest?

Takeda announced this week it is exiting the cell therapy market, and FDA issues three draft guidances to facilitate development of cell & gene therapies. How is the advanced therapies market faring thus far in 2025?